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ABSTRACT
Background. Kidney transplantation should improve abnormalities that are common during dialysis treatment, like anaemia
and mineral and bone disorder. However, its impact is incompletely understood. We therefore aimed to assess changes in
clinical indicators after the transition from chronic dialysis to kidney transplantation.
Methods. We used European Renal Association–European Dialysis and Transplant Association Registry data and
included adult dialysis patients for whom data on clinical indicators before and after transplantation (2005–15) were
available. Linear mixed models were used to quantify the effect of transplantation and of time after transplantation for
each indicator.
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Results. In total, 16 312 patients were included. The mean age at transplantation was 50.1 (standard deviation 14.2) years,
62.9% were male and 70.2% were on haemodialysis before transplantation. Total, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol and triglycerides increased right after transplantation but decreased thereafter.
All other indicators normalized or approached the target range soon after transplantation and these improvements
were sustained for the first 4 years of follow-up. In patients with higher estimated glomerular filtration rate (eGFR) levels
(30–60 and >60 mL/min/1.73 m2), the improvement of haemoglobin, ferritin, ionized calcium, phosphate, parathyroid
hormone, HDL cholesterol, triglycerides, albumin and C-reactive protein levels was more pronounced than in patients with
a lower eGFR (<30 mL/min/1.73 m2).
Conclusions. Except for total cholesterol, LDL cholesterol and triglycerides, all clinical indicators improved after
transplantation. These improvements were related to eGFR. Nevertheless, values remained out of range in a considerable
proportion of patients and anaemia and hyperparathyroidism were still common problems. Further research is needed to
understand the complex relationship between eGFR and the different clinical indicators.
Keywords: anaemia, dialysis, dyslipidaemia, inflammation, kidney transplantation, mineral metabolism
INTRODUCTION
Patients with end-stage kidney disease need renal replacement
therapy (RRT) to maintain the balance of fluid and metabolic
components in the body. Although kidney transplantation pro-
vides better patient survival and quality of life, most patients
need to start RRT on dialysis treatment because of the lack of
available donor kidneys [1].
In dialysis patients, disorders like anaemia and mineral and
bone disorders are common. Patients treated with either hae-
modialysis or peritoneal dialysis need erythropoiesis-stimulat-
ing agents (ESAs), and even with administration of ESA,
haemoglobin levels achieved may be suboptimal [2]. Mineral
and bone disorders are also an important problem. The
European multicentre COSMOS study (Current Management of
Secondary Hyperparathyroidism: a Multicentre Observational
Study) showed that only 77, 27 and 56% of haemodialysis
patients achieved the target levels for calcium, phosphate and
parathyroid hormone (PTH), respectively [3]. Furthermore, in-
flammatory markers such as C-reactive protein (CRP) are higher
in dialysis patients and are associated with higher cardiovascu-
lar morbidity and mortality [4–7].
Kidney transplantation can improve many of these clinical
indicators. Previous studies showed an increase in haemoglobin
and albumin, a transient increase in cholesterol and a decrease
in ferritin, phosphate and PTH levels [8–10]. However, these
studies reported only on the first year post-transplantation and
were performed in a single centre or country. To our knowledge,
international studies with long-term follow-up have not yet
been performed. In this study, we therefore used data from the
European Renal Association–European Dialysis and Transplant
Association (ERA-EDTA) Registry to assess whether kidney
transplantation is associated with changes in clinical indicators
and how each clinical indicator changes over time after kidney
transplantation. We focused on haemoglobin and iron status,
mineral and bone metabolism, lipid profile, inflammation and
malnutrition.
MATERIALS ANDMETHODS
Study population
National and regional renal registries within Europe provide
yearly data on patients treated with RRT to the ERA-EDTA
Registry [11]. The core dataset includes month and year of birth,
sex, primary renal disease (PRD), treatment modality at the start
of RRT, changes in RRT modality and date and cause of death.
Recently the registry has extended its data collection with labo-
ratory measurements. For this study we included the following
national and regional renal registries that provided laboratory
data for both dialysis and transplanted patients: Denmark (in-
clusion period 2005–15), Finland (2010–15), Norway (2005–15),
Catalonia (Spain, 2010–15) and UK (England, Wales and
Northern Ireland, 2005–15). All registries followed their national
legislation with regard to ethics committee approval.
Patients 20 years of age who fulfilled the following criteria
were included: first kidney transplantation between 2006 and
2015, 3 months of dialysis treatment before receiving a first
kidney transplant and availability of one or more clinical indica-
tor measurement while on dialysis within 1 year before kidney
transplantation and one or more measurement within 4 years
after transplantation.
Data collection and definitions
PRD was classified into six groups: glomerulonephritis (GN), dia-
betes mellitus, hypertension/renal vascular disease (HT/RVD),
polycystic kidney disease, other causes of renal failure and
unknown. To study the influence of time, the year of kidney
transplantation was divided into the time periods 2006–10 and
2011–15.
The clinical indicators studied were categorized into four
groups: anaemia (haemoglobin and ferritin), mineral and bone
disorders (serum ionized calcium, phosphate and PTH), dyslipi-
daemia [total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol and triglycerides]
and inflammation and malnutrition (serum albumin and CRP).
Laboratory variables were determined according to local practice.
An overview of the availability of clinical indicators is given
in Supplementary data, Table S1. The registries of Denmark,
Finland, Norway and Catalonia provided one laboratory mea-
surement per patient per year. The Danish registry provided the
date of each measurement, whereas these dates were unknown
for the other registries. The UK Renal Registry provided one mea-
surement per quarter (date unknown). The estimated glomerular
filtration rate (eGFR) was calculated using the Chronic Kidney
Disease Epidemiology Collaboration creatinine equation [12].
Statistical analysis
Patient characteristics were summarized using percentages,
mean values with standard deviations (SDs) and median values
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with interquartile ranges (IQRs). For the main analysis, data
from all registries were combined. When multiple measure-
ments per year were available, we calculated an average value
per patient per calendar year. For the year of kidney transplan-
tation, we only used measurements after transplantation. As
this could only be determined for Denmark and the UK (used
measurement in the quarter after quarter of transplantation),
measurements in the year of transplantation represent only
patients from these two countries.
To quantify the changes in the clinical indicators, we applied
two different linear mixed models with and without adjustment
for potential confounders (age at transplantation, sex, PRD, pe-
riod of transplantation and country) using the SAS software
‘proc mixed’ procedure (SAS Institute, Cary, NC, USA). These
models, also known as multilevel models, take into account the
dependency between multiple measurements from the same
patient. Model 1 examined the effect of kidney transplantation
on the level of the clinical indicator, including the measurement
in the year before and the first measurement after transplanta-
tion. Model 2 examined the effect of time after transplantation
on the level of the clinical indictor, including only post-
transplantation measurements.
For all clinical indicators we reported the percentages below,
within and above the targets as defined in guidelines for dialy-
sis patients [13–15] and for transplant recipients [16–18].
To show the short-term changes in clinical indicators, we
performed further analyses including only Denmark and the
UK, which provided the measurement date or period. These
analyses present the course over time for haemoglobin, ferritin,
phosphate, PTH and total cholesterol in 3-month periods be-
tween 1 year before and 4 years after transplantation. The linear
mixed model was applied to identify at which time point clini-
cal indicators had changed statistically significantly from the
last time point pre-transplantation. Additional analyses were
performed to examine changes in dyslipidaemia including only
those registries with data for all lipid indicators (Denmark,
Finland and Norway). Since the UK data comprised 75% of the
dataset, sensitivity analyses excluding the UK were used to as-
sess whether the results remained the same.
Subgroup analyses were performed for age at transplanta-
tion, sex, PRD, kidney donor source (living versus deceased) and
time period (2006–10 versus 2011–15). Additional subgroup anal-
yses were used to test for the association between eGFR (<30
versus 30–59 versus 60 mL/min/1.73 m2), albumin (<35 versus
35–50 versus >50 g/L), CRP (<10 versus 10 mg/L) and PTH
(<45 versus 45 pmol/L) levels 1 year post-transplantation and
changes in the clinical indicators after transplantation.
All analyses were performed using SAS software (version 9.4;
SAS Institute). We considered P-value <0.05 (two-sided) as sta-
tistically significant.
RESULTS
Patient characteristics
In total, 16312 patients were included in the study. Table 1
presents the demographic and clinical patient characteristics.
The majority of patients were men (62.9%) and the mean age
was 47.1 [standard deviation (SD) 14.1] years at the start of RRT
and 50.1 (SD 14.2) years at transplantation. Haemodialysis was
the most common dialysis modality (70.2%) and the median
time on dialysis before transplantation was 2.3 years.
Clinical indicators
Figure 1 shows the median levels of each clinical indicator in
the year before transplantation, right after transplantation and
in the years thereafter. In Table 2, the results of the mixed mod-
els are presented; it shows the unadjusted and adjusted effects
of kidney transplantation on the clinical indicators (Model 1)
and of time per year after transplantation (Model 2). The unad-
justed and adjusted models yielded very similar results for
all indicators. Below we present the results of the adjusted
analyses.
Table 1. Demographic and clinical characteristics of patients
(N¼16 312)
Characteristics
Descriptive
statistics
Gender, n (%)
Male 10 257 (62.9)
Female 6055 (37.1)
Age at start RRT (years)
Mean 6 SD 47.1 6 14.1
Age at kidney transplantation (years)
Mean 6 SD 50.1 6 14.2
PRD, n (%)
Diabetes 2620 (16.1)
HT/RVD 1416 (8.7)
GN 3581 (22.0)
Polycystic kidney disease 2170 (13.3)
Other causes 4088 (25.1)
Unknown 2437 (14.9)
Last dialysis modality before kidney transplanta-
tion, n (%)
Haemodialysis 11 444 (70.2)
Peritoneal dialysis 4868 (29.8)
Countries/regions, n (%)
Denmark 1068 (6.6)
Catalonia (Spain) 967 (5.9)
Finland 799 (4.9)
Norway 1144 (7.0)
UK (England, Wales, Northern Ireland) 12 334 (75.6)
Dialysis vintage at the time of kidney transplan-
tation (years), median (IQR)
2.3 (1.24.1)
eGFR 1-year post-kidney transplantation
(mL/min/1.73 m2), mean 6 SD
55.2 6 22.5
<30, n (%) 1753 (11.3)
30–60, n (%) 8033 (51.8)
>60, n (%) 5719 (36.9)
Year of kidney transplantation, n (%)
2006–10 7637 (46.8)
2011–15 8675 (53.2)
Clinical indicators before kidney transplantation,
median (IQR)
Haemoglobin (g/dL) 11.5 (10.9–12.2)
Ferritin (ng/mL) 340 (207–501)
Ionized calcium (mmol/L) 1.19 (1.14–1.24)
Phosphate (mmol/L) 1.63 (1.38–1.92)
PTH (pmol/L) 31.1 (17.0–53.4)
Total cholesterol (mmol/L) 4.15 (3.50–4.90)
HDL cholesterol (mmol/L) 1.17 (0.91–1.47)
LDL cholesterol (mmol/L) 2.15 (1.56–2.80)
Triglycerides (mmol/L) 1.40 (1.01–2.08)
Albumin (g/L) 39 (35–42)
CRP (mg/L) 3.0 (1.4–7.0)
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Anaemia. Haemoglobin levels increased in the first year after
kidney transplantation (Figure 1A and B) {0.90 g/dL [95% confi-
dence interval (CI) 0.87–0.93]} and continued to increase 0.17 g/
dL (95% CI 0.16–0.18) in each year thereafter (Table 2). The per-
centage of anaemic patients decreased from 75.7% before trans-
plantation to 31.5% at 4 years after transplantation (Table 3).
Also, ferritin increased after kidney transplantation [81.1 ng/mL
(95% CI 71.6–90.5)]. However, thereafter it decreased [47.2 ng/
mL/year (95% CI 50.0 to 44.4)] (Figure 1C and Table 2). The
percentage of patients meeting the target for ferritin increased
from 42.2% pre-transplantation to 72.9% at 4 years after trans-
plantation (Table 3).
Mineral and bone disorders. Ionized calcium levels slightly in-
creased after kidney transplantation and remained stable in the
years thereafter (Figure 1D). The proportion of patients who
met the target was relatively high and increased over 4 years
(from 69.9% to 83.1%). Conversely, phosphate levels dropped
after transplantation [0.76 mmol/L (95% CI 0.77 to 0.76)] and
remained stable and within the target range post-transplantation
FIGURE 1: Median levels for each clinical indicator in the calendar year before, of and after kidney transplantation. Values in the year of kidney transplantation are
based on measurements after kidney transplantation only. Vertical lines extend from the 25th to 75th percentiles. The grey area indicates the target range. If this was
different for patients on dialysis, then the target range for dialysis patients is also shown.
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Table 2. Unadjusted and adjusted effects of kidney transplantation and time (in years) on clinical indicators
Clinical indicator
Effect of kidney transplantation, estimate (95% CI)
Unadjusted Adjusteda
Effect of Tx Effect of time per 1 year after Tx Effect of Tx Effect of time per 1 year after Tx
Haemoglobin (g/dL) 0.95 (0.92; 0.97) 0.17 (0.17; 0.18) 0.90 (0.87; 0.93) 0.17 (0.16; 0.18)
Ferritin (ng/mL) 81.7 (72.3; 91.1) 248.1 (250.9; 245.3) 81.1 (71.6; 90.5) 247.2 (250.0; 244.4)
Ionized calcium (mmol/L) 0.09 (0.09; 0.10) 20.01 (20.01; 20.01) 0.09 (0.09; 0.10) 20.01 (20.01; 20.01)
Phosphate (mmol/L) 20.76 (20.77; 20.75) 0.02 (0.02; 0.02) 20.76 (20.77; 20.76) 0.02 (0.02; 0.02)
PTH (pmol/L) 223.8 (224.6; 223.0) 20.95 (21.08; 20.83) 223.3 (224.1; 222.4) 20.93 (21.06; 20.80)
Total cholesterol (mmol/L) 0.41 (0.39; 0.44) 20.05 (20.06; 20.04) 0.41 (0.39; 0.43) 20.05 (20.06; 20.05)
HDL cholesterol (mmol/L) 0.14 (0.12; 0.16) 0.00 (0.00; 0.01) 0.14 (0.12; 0.16) 0.00 (0.00; 0.01)
LDL cholesterol (mmol/L) 0.31 (0.22; 0.40) 20.09 (20.12; 20.07) 0.36 (0.27; 0.46) 20.10 (20.12; 20.07)
Triglyceride (mmol/L) 0.11 (0.04; 0.18) 20.07 (20.09; 20.05) 0.17 (0.10; 0.24) 20.07 (20.09; 20.05)
Albumin (g/L) 2.62 (2.42; 2.82) 20.20 (20.25; 20.14) 2.57 (2.38; 2.77) 20.23 (20.29; 20.17)
CRP (mg/L) 20.15 (1.37; 1.07) 20.06 (20.61; 0.49) 0.43 (0.81; 1.67) 0.12 (0.45; 0.69)
aModels were adjusted for age at transplantation, sex, PRD, period of transplantation and country. Results in bold are statistically significant.
TX, kidney transplantation.
Table 3. Percentages of patients below, within or above the target range for clinical indicators in the calendar year before (1), of (TX) and after
kidney transplantation (1–4)
Clinical indicator Level
Calendar year before, of and after kidney transplantation
1 (%) TX (%) 1 (%) 2 (%) 3 (%) 4 (%)
Haemoglobina (g/dL) Low 75.7 (83.1) 53.9 34.9 30.8 31.0 31.5
Normal 24.3 (16.8) 45.8 64.6 68.6 68.6 68.1
High 0 (0) 0.3 0.5 0.6 0.4 0.4
Ferritinb (ng/mL) <15 (<100) 0.2 (7.6) 1.4 2.8 3.7 3.1 3.6
15–300 (100–500) 42.2 (67.3) 43.8 58.9 66.2 70.3 72.9
300 (500) 57.7 (25.1) 54.9 38.3 30.1 26.6 23.5
Ionized calcium (mmol/L) <1.15 26.6 3.4 4.0 4.6 5.6 6.1
1.15–1.35 69.9 74.8 81.6 84.8 82.3 83.1
1.35 3.4 25.5 16.6 13.3 12.0 10.9
Phosphate (mmol/L) <0.7 0.3 20.0 7.9 7.2 6.6 6.6
0.7–1.5 35.5 78.2 90.5 91.0 91.4 91.3
1.5 64.3 1.8 1.7 1.8 2.0 2.0
PTHb (pmol/L) <2 (<14) 2.3 (19.3) 3.0 3.2 3.3 3.3 4.1
2–7 (14–64) 5.4 (62.6) 14.7 19.4 20.9 21.4 21.8
7 (64) 92.3 (18.1) 82.3 77.4 75.8 75.3 74.1
Total cholesterol (mmol/L) <5.2 81.9 69.6 73.4 75.1 76.2 77.1
5.2 18.1 30.4 26.6 24.9 23.8 22.9
HDL cholesterol (mmol/L) <1.0 28.9 15.6 17.1 18.6 18.4 18.3
1.0 71.1 84.4 82.9 81.4 81.6 81.7
LDL cholesterol (mmol/L) <2.6 67.2 30.6 53.4 55.7 59.2 58.5
2.6 32.8 69.4 46.6 44.3 40.9 41.5
Triglyceride (mmol/L) <1.7 61.0 38.8 57.1 61.0 63.2 61.0
1.7 39.0 61.2 42.9 39.0 36.8 39.0
Albumin (g/L) <35 22.4 11.6 8.1 6.8 8.2 8.4
35–50 77.3 88.1 90.9 92.1 90.7 91.1
>50 0.3 0.3 1.0 1.2 1.0 0.4
CRP (mg/L) <10 81.6 75.1 85.1 85.4 83.5 86.2
10 18.4 24.9 14.9 14.6 16.5 13.8
aThe normal range differs for men (low <13, normal 13–18, high >18 g/dL) and women (low <11.5, normal 11.5–16.5, high >16.5 g/dL). For patients on dialysis, reference
values for dialysis patients were used (men: low <13, normal 13–17, high >17 g/dL; women: low <12, normal 12–17, high >17 g/dL).
bFor patients on dialysis, reference values for dialysis patients (in parentheses) were used.
Values in the year of kidney transplantation are based on measurements after kidney transplantation only.
TX, kidney transplantation.
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(Figure 1F and Table 2). The percentage of patients with target
levels of phosphate improved from 35.5% pre-transplantation to
91.3% 4 years later (Table 3). Although PTH levels decreased after
transplantation [23.3 pmol/L (95% CI 24.1 to 22.4)] and contin-
ued to decline yearly by 0.93 pmol/L (95% CI 1.06 to 0.80)
(Figure 1G and Table 2), the majority of patients (74.1%) still had
hyperparathyroidism 4 years post-transplantation (Table 3).
Dyslipidaemia. We observed an increase in the levels of all lipid
indicators after transplantation (Figure 1H–K and Table 2).
Thereafter, total cholesterol, LDL cholesterol and triglyceride
levels slightly decreased yearly, whereas HDL cholesterol
remained stable. The percentage of patients with hypercholes-
terolaemia increased right after transplantation (from 18.1% to
30.4%) and decreased thereafter (22.9% at 4 years). However, it
remained higher than before transplantation (Table 3). Shortly
after transplantation, 69.4% of patients had high LDL cholesterol
(2.6 mmol/L) and this decreased to 41.5% at 4 years after trans-
plantation, whereas the percentage of patients with hypertrigly-
ceridaemia remained stable at 40% after a peak right after
transplantation (61.2%). The percentage of patients achieving
the target for HDL cholesterol increased from 71.1% to 81.7%.
Inflammation and malnutrition. Albumin levels increased by
2.57 g/L (95% CI 2.38–2.77) after kidney transplantation and
thereafter slightly decreased 0.23 g/L (95% CI 0.29 to 0.17) per
year (Figure 1L and Table 2). The percentage of patients meeting
the albumin target increased from 77.3% pre-transplantation to
91.1% 4 years post-transplantation (Table 3). In contrast, CRP
levels did not change. Elevated CRP levels (10 mg/L) were most
common in the year of transplantation (24.9%) and decreased
thereafter (13.8% at 4 years post-transplantation), which was
lower than pre-transplantation (Table 3).
We explored the change of clinical indicators within the
first year post-transplantation in an analysis including only
Denmark and the UK and found that haemoglobin, ferritin,
phosphate, PTH and total cholesterol levels significantly
changed within 3 months after transplantation (Supplementary
data, Figure S1). A sensitivity analysis including only Denmark,
Finland and Norway, which had complete data on lipid profiles,
showed that the patterns for all lipid indicators in these three
countries were not different than those found in the main
analysis. Finally, repeating the analysis without the UK showed
similar patterns over time for all clinical indicators and did not
change our conclusions.
Subgroup analyses
We found that haemoglobin levels showed a larger increase for
younger versus older patients, men versus women, patients
with GN versus those with other PRDs, those who received a
kidney from a living versus a deceased donor and those who re-
ceived their transplant between 2011–15 and 2006–10. Similarly,
decreases in ferritin and phosphate levels were more pro-
nounced in these subgroups (Table 4).
The improvements of haemoglobin, ferritin, ionized calcium,
phosphate, PTH, HDL cholesterol, triglycerides, albumin and
CRP levels were associated with eGFR 1 year post-
transplantation, with better results in the subgroups with
higher eGFR levels. Patients with albumin levels in the target
range (35–50 g/L) had higher haemoglobin and HDL cholesterol
and lower phosphate, PTH and CRP levels compared with those
with lower albumin levels. Low CRP levels (<10 mg/L) were asso-
ciated with high haemoglobin and albumin levels. Finally, lower
phosphate levels and higher total and LDL cholesterol and tri-
glyceride levels were found in patients with high PTH levels
(45 pmol/L) when compared with those with lower levels
(Figure 2 and Table 5).
DISCUSSION
In this study we assessed the patterns of clinical indicators re-
lated to anaemia, mineral and bone metabolism, inflammation
and malnutrition during the transition period from dialysis
treatment to kidney transplantation. All clinical indicators nor-
malized or at least approached the target range soon after kid-
ney transplantation. These improvements were sustained
during 4 years of follow-up. Furthermore, total cholesterol, LDL
cholesterol, HDL cholesterol and triglycerides increased directly
after transplantation but decreased thereafter.
This study found an increase in haemoglobin levels in the
first year post-transplantation. The percentage of anaemic
patients decreased from 75.7% to 31.5% at 4 years after trans-
plantation. Also, Jones et al. [19] showed for 530 patients that
haemoglobin levels increased in the first 2 years after kidney
transplantation and that the prevalence of anaemia decreased
from 89.4% pre-transplantation to 44.3% post-transplantation.
These findings were confirmed in some smaller studies [20, 21].
Although the transplanted kidney can improve haemoglobin
levels, many patients still do not achieve the target levels [19,
22]. Likewise, we found a post-transplant anaemia prevalence
of up to 30% in the 4-year follow-up period that was predomi-
nantly present in the subgroups with lower kidney function
(eGFR <30 and 30–59 versus 60 mL/min/1.73 m2). However, not
only kidney function, but also male gender, African American
race, low serum bicarbonate and the use of angiotensin-con-
verting enzyme inhibitors, angiotensin II receptor antagonists
and prednisone were shown to be associated with post-
transplant anaemia [19, 20]. Based on these findings, we suggest
that workup for other causes of anaemia could be useful for
patients in whom the anaemia is not corrected within 1 year
post-transplantation. In addition, we found that after trans-
plantation, ferritin levels decreased and the percentage of
patients meeting the target almost doubled. This finding could
be explained by the fact that patients usually stop receiving in-
travenous iron after transplantation. However, other factors
could play a role, because ferritin is not only representative for
iron storage, it is also affected by infection, inflammation, liver
disease and malignancy [23].
In line with previous studies [24, 25], we found an increase in
ionized calcium levels in the first 3 months post-transplantation,
which stabilized thereafter. Also, the percentage of patients within
the normal range was stable. Hypophosphataemia is common in
the early post-transplantation period, whereas phosphate levels
commonly return to normal in the following year, with >90% of
patients meeting the target [24, 26]. Similarly, phosphate levels de-
creased dramatically after transplantation and then slightly in-
creased along the lower boundary of the target range for healthy
individuals. Sirilak et al. [27] reported continuous renal phosphate
loss during a median follow-up of 5.7 years and concluded that hy-
perparathyroidism might play a role in this phenomenon rather
than the phosphaturic hormone fibroblast growth factor 23. The
current findings support the recommendations from the Kidney
Disease: Improving Global outcomes group to monitor calcium and
phosphate regularly after kidney transplantation [28]. Furthermore,
our study showed a dramatic decrease in PTH levels in the first 3
months post-transplantation, remaining stable thereafter.
However, in the majority of transplant recipients, PTH levels were
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still higher than recommended for healthy individuals, which
shows that even with good excretory function, the kidney allograft
cannot normalize the PTH level [9, 10, 29, 30]. In most cases, tertiary
hyperparathyroidism is probably the problem [31, 32]. The impact
of hyperparathyroidism post-kidney transplantation is well
recognized. Previous studies found associations between hyper-
parathyroidism and increased risk of fractures, graft loss, cardio-
vascular events and all-cause mortality [25, 29, 31, 32]. Thus the
surveillance and treatment of hyperparathyroidism after trans-
plantation may contribute to the prevention of poor outcomes in
kidney transplant recipients.
This study showed an increase in total cholesterol, LDL cho-
lesterol and triglycerides to levels higher than the target ranges
only in the early post-transplantation period (3–6 months).
Thereafter they decreased gradually into the target range,
which could be due to lower doses of immunosuppressive drugs
and/or the initiation of lipid-lowering therapy. Similarly, the
percentages of patients with hypercholesterolaemia, high LDL
cholesterol and hypertriglyceridaemia modestly increased the
first year of transplantation. The increase in total cholesterol
can be explained by an increase in LDL cholesterol. This finding
is in line with other recent studies [10, 33]. In contrast, an older
FIGURE 2: Median levels for each clinical indicator in the calendar year before, of and after kidney transplantation by eGFR level at 1-year post-transplant (<30, 30–59
and >60 mL/min/1.73 m2). Values in the year of kidney transplantation are based on measurements after kidney transplantation only.
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study performed between 1976 and 1991 [34] showed persis-
tently elevated total cholesterol, LDL cholesterol and triglycer-
ide levels over a mean follow-up of 7 years. Possibly the
patterns of lipid profiles differ over time due to a changing trend
in immunosuppressive regimens. In the past, corticosteroids
and cyclosporine, which were proven to induce hypercholester-
olaemia, were used as the main regimens [35, 36], whereas the
majority of clinicians nowadays choose tacrolimus, mycophe-
nolate mofetil and as low as possible doses of corticosteroids
[37].
Albumin levels increased early after transplantation, fol-
lowed by a slight decline after 1 year. About 90% met the target
and this proportion remained stable during the 4-year follow-
up. A similar pattern was found by Guijarro et al. [7]. In addition,
we found that CRP rose transiently in the year of transplanta-
tion and declined thereafter. This increase might be related
with alloimmunity and ischaemia–reperfusion injury [38] and
the occurrence of early post-transplant infection [39].
Surprisingly, we found that the great majority of patients was
not inflamed and had normal CRP levels both before and after
transplantation. This may be due to the better health status of
patients selected for transplantation when compared with dial-
ysis patients. However, it should be kept in mind that CRP may
be measured only in those patients in whom an infection is sus-
pected or needs to be excluded. Many studies found an associa-
tion between high CRP and decreased long-term allograft
function and increased risk of coronary events [4, 5, 40], sup-
porting the idea that caution is required in case of elevated CRP
levels in transplant recipients.
This study provides useful information about the course of
clinical indicators directly and later post-transplantation, which
reflects both kidney allograft function in recipients and the clin-
ical practice of physicians in European countries. The major
strengths of this study are the use of multinational data, long
follow-up period and large sample size. However, there are also
some limitations, most of which are related to the fact that this
study was based on registry data. First, data on the use of medi-
cation were unavailable, whereas, in particular, immunosup-
pressive drugs, ESAs, iron supplementation, lipid-lowering
therapies and vitamin D might have influenced the results.
Second, clinical information, such as the occurrence of infec-
tions, allograft rejection or any illness that might have affected
the levels of the clinical indicators, was unavailable. Third,
there was considerable variation in the number of measure-
ments of clinical indicators between countries/regions. We
therefore performed sensitivity and subgroup analyses to exam-
ine the robustness of the results. Finally, we did not have infor-
mation on the laboratory measurement methods used.
In conclusion, except for total cholesterol, LDL cholesterol
and triglycerides, all other investigated clinical indicators im-
proved after kidney transplantation. These improvements were
related to eGFR. Nevertheless, values remained out of range in a
considerable proportion of transplant recipients and particu-
larly anaemia and hyperparathyroidism were still common
problems. Datasets containing more clinical information, espe-
cially on the use of medication, are needed to understand the
complex relationship between eGFR and the different clinical
indicators.
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